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The Philadelphia chromosome-negative
myeloproliferative neoplasms (MPN) are
a group of clonal hematopoietic diseases
characterized by bone marrow prolifera-
tion of one or more of the myeloid cell
lineages with no marked alterations in cel-
lular maturation. MPN classically comprise
the clinically and pathologically related
polycythemia vera (PV), essential thro-
mobocythemia (ET), and primary myelofi-
brosis (PMF). Identification of the JAK2
V617F mutation has revolutionized the
molecular diagnosis of MPN as this muta-
tion is present in >95% of patients with
PV and in 50% of patients with ET
and PMF. In PV and ET, the potential
exists for the disease to transform to a
myelofibrotic stage and, together with PMF,
transformation to acute myeloid leukemia
(AML). The introduction of small mole-
cule inhibitors that abrogate both normal
and mutant JAK protein intracellular sig-
naling in PMF has undoubtedly been a
major advance in the treatment of these
types of malignancies (1). Nevertheless,
the only potentially curative option for
these diseases, particularly PMF, is allo-
geneic stem cell transplantation (ASCT).
Though ASCT was previously considered
only for those patients with advanced
or transformed disease, improvements in
candidate patient selection and strati-
fication, timing of transplantation, and
conditioning regimens have significantly
reduced the transplant related morbid-
ity and increased the overall survival for
MPN patients undergoing this procedure
(2). However, as relapse is a major cause
of treatment failure post-ASCT with sal-
vage options limited and subsequent out-
come relatively poor, identification of those
patients at high-risk of relapse would
be highly desirable, potentially enabling
therapeutic intervention before overt
relapse.
Conventionally, donor chimerism status
is used to assess engraftment post-ASCT
for hematological malignancies. Compar-
ison of donor and recipient profiles can
be achieved by either short tandem repeat
(STR) analysis or quantitative polymerase
chain reaction (qPCR) possessing sensitiv-
ities of 1–2%, with post-ASCT surveil-
lance performed at one to three-monthly
intervals. Post-ASCT monitoring utilizing
additional patient-specific markers is most
likely to provide a more beneficial, person-
alized profile with this approach already
applied to many MPN patients under-
going ASCT. Early studies demonstrated
the achievement of a molecular remis-
sion in JAK2 V617F-positive MPN post-
ASCT using qualitative PCR (3). Devel-
opment of more sensitive, JAK2 V617F-
specific qPCR methodologies capable of
detecting one mutant allele in 104 wild
type copies has subsequently been shown
to provide information on the rate of dis-
ease eradication and the identification of
patients, at defined time points post-ASCT,
at an increased risk of relapse (4–6). These
sensitive JAK2 V617F qPCR assays have
also been shown to be of value in trig-
gering adoptive immunotherapies such as
donor lymphocyte infusions that are able
to elicit a graft-versus-tumor effect both
preemptively and for salvage, post-relapse
(7, 8). Even so, such qPCR methodologies
require optimization across platforms and
rigorous attention to reliability and sen-
sitivity to ensure continued clinical util-
ity (9). Mutations of MPL that encodes
the receptor for thrombopoietin are also
recurrent in ET and PMF but at a much
lower frequency than the JAK2 V617F.
In those reported MPL-mutation positive
MPN who have undergone ASCT, rapid
clearance of theMPL W515L mutation cor-
related well with peripheral blood counts
and donor chimerism status (10).
More recently, whole exome sequenc-
ing has identified insertion and/or deletion
mutation in CALR, a gene that encodes
the endoplasmic reticulum-associated, cal-
cium binding protein calreticulin. These
mutations, which occur exclusively in
CALR exon nine, appear not to be found in
PV, and are present in up to 80% of ET and
PMF patients who are JAK2 V617F-and
MPL-negative (11, 12). As CALR muta-
tions are likely initiating events in MPN
pathogenesis, the possibility arises to assess
these mutations as markers of residual dis-
ease in MPN patients post-ASCT. An initial
assessment of CALR mutant allele bur-
den, using semi-quantitative PCR fragment
analysis, has shown that eradication and
persistence of CALR mutations mirror
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JAK2, MPL, CALR,
& other mutations
Donor chimerism
Applicable to all patients
Moderate sensitivity
qPCR
Applicable to point mutations
Good sensitivity
PCR fragment analysis
Applicable to CALR mutations
Moderate sensitivity
Sanger sequencing
Applicable to all mutations
Limited sensitivity
NGS
Applicable to all mutations
Moderate sensitivity
Not yet proven in the
post-ASCT setting
dPCR
Applicable to point mutations
Good sensitivity
Not yet proven in the
post-ASCT setting
FIGURE 1 | Summary of methodologies for monitoring MPN-specific mutations post-allogeneic stem cell transplantation. ASCT, allogeneic stem cell
transplantation; MPN, myeloproliferative neoplasm; qPCR, quantitative polymerase chain reaction; NGS, next generation sequencing; and dPCR, digital
polymerase chain reaction.
donor chimerism status providing ini-
tial validation for future prospective ser-
ial monitoring of CALR mutations post-
ASCT (13).
Apart from the common JAK2 V617F,
MPL, and CALR mutations, several other
recurrent mutations are observed in MPN
but are also present in the myelodys-
plastic syndromes (MDS), MDS/MPN
syndromes, and AML limiting their diag-
nostic utility but affording the potential
for their use as markers of residual dis-
ease. These include mutations of TET2,
ASXLI, CBL, NRAS, and EZH2. Rarely,
mutations within some of these genes have
been demonstrated in normal individuals
(14) advocating caution when employed as
markers of residual disease. Next genera-
tion sequencing (NGS) technologies now
afford the opportunity to identify path-
ogenic mutations in multiple amplicons
from these and many other genes simulta-
neously. A recent proof of principle study
has utilized NGS to identify molecular
mutations in MDS/MPN patients pre-
ASCT with detection of the corresponding
mutation in the post-ASCT period pre-
dictive of relapse (15). Whereas qPCR
techniques provide relative quantitation of
target amplicons, the emerging technology
of digital PCR (dPCR) allows the absolute
quantitation of mutant alleles with very
small fold changes quantifiable. This
approach has been applied to detect and
monitor extremely low levels of BCR-ABL1
transcripts in chronic myeloid leukemia
and acute lymphoblastic leukemia patients
who have achieved deep molecular
responses with tyrosine kinase inhibitor
therapy (16, 17).
Whether NGS technologies will be of
value in routine practice in the post-ASCT
setting remains to be proven. Currently,
limits of detection require improvement
in order to approach those achieved by
qPCR necessary for clinical application
(Figure 1). Furthermore, issues such as
intra- and inter-laboratory will require
addressing for both NGS and dPCR; pre-
liminary studies with NGS have demon-
strated technical feasibility and concor-
dance in the diagnostic setting (18). These
emerging methodologies might soon be
applied to identify and monitor muta-
tional events enabling a distinct, per-
sonalized profile in those MPN patients
undergoing ASCT. The goal would be
the prompt recognition of those patients
with an increased risk of relapse in which
early therapeutic intervention is warranted,
ultimately leading to gains in long-term
disease-free and overall survival.
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